PMID: 9169309Apr 1, 1997Paper

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
H BerzewskiC A Gagiano

Abstract

A 6-week, randomised, double-blind, multicentre study in 256 patients with a DSM-III-R diagnosis of major depression was carried out to compare the selective noradrenaline reuptake inhibitor (NARI), reboxetine, with the reference standard tricyclic antidepressant, imipramine. The efficacy of reboxetine, as measured by the extent of improvement of Hamilton Depression Rating Scale. Montgomery and Asberg Depression Rating Scale and the Clinical Global Impression Scale, was similar to that of imipramine. The improvement was observed in the overall population and in severely depressed and melancholic patients. Reboxetine tolerability compared favourably with that of imipramine. Frequency of discontinuation due to adverse events was lower in the reboxetine-treated group (10.0%) than in the imipramine-treated group (14.3%), and the cumulative risk of development (Kaplan-Meier analysis) of dry mouth, hypotension and/or related symptoms and tremor was significantly higher on imipramine than on reboxetine.

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Apr 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·G Beaumont
Jun 11, 1983·British Medical Journal·B R Ballinger, J Feely
Mar 1, 1995·British Journal of Clinical Pharmacology·N TheofilopoulosC M Bradshaw
Mar 1, 1994·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON

❮ Previous
Next ❯

Citations

Oct 7, 2004·Aging Clinical and Experimental Research·Patrizia MecocciUmberto Senin
Nov 15, 2007·European Journal of Nuclear Medicine and Molecular Imaging·Akihiro TakanoBalázs Gulyás
Mar 21, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Akihiro TakanoChrister Halldin
Mar 25, 2011·Attention Deficit and Hyperactivity Disorders·Javier QuinteroNatalia García-Campos
Jun 5, 2002·European Journal of Pharmacology·Catherine VilpouxJean Costentin
Dec 21, 2000·Journal of Affective Disorders·S A MontgomeryJ Zajecka
Mar 2, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S Kasper, R Wolf
Sep 5, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·N BrunelloG Racagni
Jun 24, 2004·The Australian and New Zealand Journal of Psychiatry·Peter Ellis, UNKNOWN Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression
Aug 29, 2003·Pharmacogenomics·Jan-Fang Cheng, Len A Pennacchio
Jan 18, 2003·Sleep Medicine Reviews·Seiji NishinoEmmanuel Mignot
Oct 31, 2006·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Thomas C BaghaiHans-Jürgen Möller
Dec 1, 2000·The Annals of Pharmacotherapy·A C Scates, P M Doraiswamy
Jun 21, 2013·Journal of Psychopharmacology·Eromona Whiskey, David Taylor
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·M Quasim, A Kumar
Jun 16, 2009·Biochemical Pharmacology·Linda P DwoskinMichael T Bardo
Sep 11, 2004·Journal of Psychopharmacology·Luigi Ferini-StrambiAnna Bianchi
Dec 7, 2002·CNS Drugs·Gin S MalhiShahzad Salim
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·C EggerC Stuppaeck
Feb 2, 1999·The British Journal of Psychiatry : the Journal of Mental Science·E Szabadi
Oct 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·Anthony S RauhutMichael T Bardo
Jul 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Dennis K MillerLinda P Dwoskin
Aug 13, 2002·Journal of Clinical Psychopharmacology·Stephen M StahlGerri E Schwartz
Aug 13, 2002·Journal of Clinical Psychopharmacology·Vittorino AndreoliMarcio Versiani
Jan 25, 2003·Journal of Clinical Psychopharmacology·Stuart MontgomeryGerri E Schwartz
Mar 27, 2003·Therapeutic Drug Monitoring·Daniel OhmanFinn Bengtsson
Jul 20, 2002·Medicine and Science in Sports and Exercise·Maria Francesca PiacentiniKenny De Meirleir
Dec 4, 2003·CNS Drug Reviews·Michelle E Page
Jun 26, 2009·Drugs & Aging·Adam DarowskiDavid J Chambers
Apr 29, 2008·CNS Spectrums·P J Goodnick
Dec 20, 2002·International Clinical Psychopharmacology·James M FergusonGerri E Schwartz
Aug 29, 2003·Pharmacogenomics·Charles E Glatt, Victor I Reus
Sep 14, 2000·International Journal of Geriatric Psychiatry·E Aguglia
Nov 3, 2004·Journal of Psychosomatic Research·L J FulkG A Hand

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
P DostertI Poggesi
Journal of Neurology, Neurosurgery, and Psychiatry
J C Breitner
© 2021 Meta ULC. All rights reserved